IPP Bureau
Glenmark receives U.S. FDA approval for Ryaltris
By IPP Bureau - January 14, 2022
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Evonik to build production plant for rhamnolipids in Slovakia
By IPP Bureau - January 14, 2022
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
LumiraDx Lab Covid-19 Antigen test detects the Omicron variant
By IPP Bureau - January 14, 2022
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
Hekka Labs introduces decentralized chronic disease data management in South Asia
By IPP Bureau - January 14, 2022
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
AstraZeneca and Scorpian Therapeutics partner to target novel cancer treatments
By IPP Bureau - January 14, 2022
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
South Korea approves Novavax Covid-19 vaccine
By IPP Bureau - January 13, 2022
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Metropolis Healthcare opens MedEngage Scholarship programme
By IPP Bureau - January 13, 2022
The last date to apply for this program is 18th January 2022
Normalised quarter with impending margin pressure: ICICI Direct
By IPP Bureau - January 13, 2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’
By IPP Bureau - January 13, 2022
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
BioGenex RT-PCR Kit detects all Covid variants in half the time
By IPP Bureau - January 13, 2022
This test analyses samples in VTM directly without the need for RNA extraction step
AstraZeneca studies show its booster effective against all variants
By IPP Bureau - January 13, 2022
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
AliveCor’ KardiaMobile gets NICE approval to detect irregular heart rhythm symptons
By IPP Bureau - January 13, 2022
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
Merck KGaA appoints Global R&D Head & CSO for healthcare business sector
By IPP Bureau - January 13, 2022
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021
By IPP Bureau - January 12, 2022
This surpasses the number of approvals supported in 2020
Novel preventive vaccine for Parkinson’s move into human trials
By IPP Bureau - January 12, 2022
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
